Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

On October 9, 2019 Nordic Nanovector ASA (OSE: NANO) reported that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with 212Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at the 2019 Annual Congress of the European Association of Nuclear Medicine (12-16 October, Barcelona, Spain) (Press release, Nordic Nanovector, OCT 9, 2019, View Source [SID1234540121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the study, the efficacy of 212Pb-NNV003 was compared with ibrutinib in a disseminated mouse model using the ibrutinib-resistant cell line MEC-2. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that forms part of the standard of care for chronic lymphocytic leukaemia (CLL) and non-Hodkgin’s lymphoma (NHL), alongside chemotherapy and anti-CD20 antibody therapy.

The study showed that a single injection of 212Pb-NNV003 is safe and effective for the treatment of CD37-positive CLL and NHL in preclinical models, with promising efficacy in an ibrutinib-resistant CLL model.

Presentation details are as follows:

Targeted alpha therapy with 212Pb-NNV003 is efficient in treatment of ibrutinib-resistant chronic lymphocytic leukaemia in preclinical model

Authors: A. Saidi, H. Heyerdahl, A.F. Maaland, J. Torgue, and J. Dahle

Session: 405 – M2M – Parallel Session: Antibody-Based Radionuclide Therapy

Abstract: OP-134

Date / time: Sunday 13 October, 14:30-14:41 CEST

The abstract book can be downloaded at View Source

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: [email protected]